



August 1st, 2017

Press Release

We are pleased to announce the takeover of the activities of Diverchim by a group of investors. This group is led by mainly Intsel Chimos, a French pharmaceutical company, and Arrhénius C&I represented by Pierre Charrier, its managing partner.

Under the management of Pierre Charrier and together with the founder of the company, Jean-Louis Brayer, Diverchim CDMO will increase its range of services offered. In particular custom manufacturing of Active Pharmaceutical Ingredients (APIs) will be increased from the present small quantities (a few grams up to hundreds of grams) to hundreds of kilograms. Simultaneously Diverchim CDMO will maintain its development and marketing of cosmetic ingredients.

In support of its « Discovery » activity, Diverchim CDMO plans during the coming months to further strengthen its research teams. This will be coupled with important investments in its laboratories, kilo-labs and pilot plant facilities in order to solidly support the development and c-GMP manufacture of APIs. As a reminder, Diverchim received its c-GMP certificate from the French health authorities in September 2015.

For more information, contact: Pierre Charrier
C.E.O
Diverchim CDMO
6 rue du Noyer Roissy-en-France
95734 Roissy CDG Cedex
Tél : 01 30 11 95 59
e-mail : pierre.charrier@diverchim.com

Diverchim:

Fine chemical company dedicated to the development and manufacture of complex organic molecules for life science industries (Custom Development & Manufacturing Organisation – CDMO) mainly specialized in the development & manufacture of pharmaceutical and cosmetic active ingredients under the current Good Manufacturing Practices. Recent “mutual recognition” thus means that Diverchim CDMO is also FDA-approved.

Intsel Chimos:

Pharmaceutical laboratory specialized in the promotion of new experimental drugs, distribution of specific drugs registered under temporary use authorization (named patient basis), supply of pharmaceuticals for clinical trials, marketing of generic injectable drugs for hospitals and the development of new orphan drugs.

Arrhénius C&I:

Consulting & Investment company, acting in the life science sector, especially for pharmaceutical industries (laboratories, CMO, CDMO, CRO) and investing in fine chemicals and biotech sectors.